Clinical findings from the JUPITER-02 trial support the use of toripalimab plus gemcitabine-cisplatin as the new standard of care for first-line treatment of patients with
In patients with metastatic urothelial carcinoma and FGFR alterations after previous immune checkpoint treatment, the pan–fibroblast growth factor receptor (FGFR) inhibitor erdafitinib significantly increased overall survival, compared
Point-of-sale prices for generic imatinib are substantially higher than the pharmacy acquisition costs from 2017 to 2023, a study of Medicare Part D beneficiaries shows.
Based on the negative results of the phase III, double-blind COSMIC 313 trial, the American Society of Clinical Oncology has updated its rapid recommendations for
In China, a phase III trial of nimotuzumab plus gemcitabine shows significantly improved overall survival (OS) and progression-free survival (PFS) in patients with locally advanced
Two research studies report positive results with the use of the highly selective potent and brain-penetrant RET inhibitor selpercatinib, including first-line treatment of advanced RET fusion–positive non–small-cell
Compared in a phase 3 trial with gemcitabine–cisplatin in patients with untreated unresectable or metastatic urothelial carcinoma, nivolumab plus gemcitabine–cisplatin resulted in significantly better outcomes,
Perioperative durvalumab improved outcomes in patients with resectable non–small-cell lung cancer (NSCLC) in a study of neoadjuvant/adjuvant immunotherapy. The authors write, “Perioperative regimens that combine
Payments from the pharmaceutical industry are associated with oncologists’ prescribing of cancer drugs of questionable benefit, according to a cohort study of fee-for-service Medicare claims.
At a 1,000-bed teaching hospital in France, drug-related problems (DRPs) occurred less frequently in older patients with cancer cared for using the RECAP (phaRmaceutical care
